JANUX THERAPEUTICS INC (JANX) Forecast, Price Target & Analyst Ratings

NASDAQ:JANX • US47103J1051

Current stock price

14.53 USD
0 (0%)
At close:
14.53 USD
0 (0%)
After Hours:

Analyst forecast overview

View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for JANUX THERAPEUTICS INC (JANX).

Forecast Snapshot

Consensus Price Target

Price Target
$54.57
+ 275.57% Upside
→ Price target details

Next Earnings Forecast

Earnings Estimate
Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.57
Revenue Estimate
2.635M
→ Full earnings forecast details

ChartMill Buy Consensus

Rating
84.62%
Weighted Analyst Rating Score
→ Analyst Ratings details

Price Target Details & History

Consensus Price Target and Range

Mean target
$54.57
Upside
+ 275.57%
From current price of $14.53 to mean target of $54.57, Based on 26 analyst forecasts
Low
$12.12
Median
$48.45
High
$105.00

Price Target Revisions

1 Month
-11.93%
3 Months
-19.85%

Price Target Summary

26 Wall Street analysts provided a forecast for the next 12 months for JANX. The average price target is 54.57 USD. This implies a price increase of 275.57% is expected in the next year compared to the current price of 14.53.
The average price target has been revised downward by 19.85% in the past 3 months.
→ Find peer stocks trading 30% below analyst price target

Analyst Ratings & History

Current Analyst Ratings

JANX Current Analyst RatingJANX Current Analyst Buy, Sell and Hold Ratings.Current Analyst Rating Strong Buy Buy Hold Sell Strong Sell 2 4 6 8 10

Analyst Ratings History

JANX Historical Analyst RatingsJANX Historical Analyst Buy, Sell and Hold Ratings and number of analysts.Historical Monthly Analyst Rating -19 -17 -15 -13 -11 -9 -7 -5 -3 -1 5 10 15 20 25

Analyst Ratings Consensus

ChartMill Buy Consensus
84.62%
JANX was analyzed by 26 analysts. The buy percentage consensus is at 85. So analysts seem to be very confident about JANX.
In the previous month the buy percentage consensus was at a similar level.
JANX was analyzed by 26 analysts, which should be a sufficient number of analysts to have a meaningful average consensus rating.
→ Find peer stocks with a buy consensus above 85%

Recent Upgrades & Downgrades

DateFirmActionFrom → To
2026-02-27Cantor FitzgeraldMaintains Overweight -> Overweight
2026-02-27GuggenheimMaintains Buy -> Buy
2026-01-20Clear StreetDowngrade Buy -> Hold
2026-01-16Piper SandlerMaintains Overweight -> Overweight
2025-12-17BarclaysMaintains Overweight -> Overweight
2025-12-02Clear StreetMaintains Buy -> Buy
2025-12-02Cantor FitzgeraldMaintains Overweight -> Overweight
2025-12-02StifelMaintains Buy -> Buy
2025-12-02B of A SecuritiesMaintains Buy -> Buy
2025-12-02HC Wainwright & Co.Maintains Buy -> Buy
2025-11-25HC Wainwright & Co.Reiterate Buy -> Buy
2025-11-18Wolfe ResearchInitiate Peer Perform
2025-11-07BarclaysMaintains Overweight -> Overweight
2025-09-17BarclaysInitiate Overweight
2025-09-10StifelReiterate Buy
2025-09-10Truist SecuritiesInitiate Buy
2025-09-04GuggenheimInitiate Buy
2025-08-19Piper SandlerInitiate Overweight
2025-07-11Raymond JamesInitiate Outperform
2025-03-03HC Wainwright & Co.Reiterate Buy -> Buy
2025-02-28ScotiaBankMaintains Sector Perform -> Sector Perform
2024-12-11Cantor FitzgeraldReiterate Overweight -> Overweight
2024-12-04ScotiaBankMaintains Sector Perform -> Sector Perform
2024-12-03Leerink PartnersMaintains Outperform -> Outperform
2024-12-03StifelMaintains Buy -> Buy

Next Earnings Forecast Details

Next Earnings Details

Release Date
May 6, 2026
Period
Q1 / 2026
EPS Estimate
-$0.57
Revenue Estimate
2.635M
Revenue Q2Q
N/A
EPS Q2Q
-49.00%
Number of Analysts
17

Next Earnings Revisions

Revenue (1 Month)
246.22%
Revenue (3 Months)
219.59%
EPS (1 Month)
7.86%
EPS (3 Months)
17.47%

Next Earnings Summary

JANX is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.57 USD and the consensus revenue estimate is 2.63M USD.
The next earnings revenue estimate has been revised upward by 219.59% in the past 3 months. Upward revisions are a positive sign and indicate that analysts are more optimistic about the next earnings compared to 3 months ago.
→ Find peers expecting at least 20% revenue growth next quarter

Full Analyst Estimates 2026 - 2033

Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates

2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033
Revenue
YoY % growth
JANX revenue by date.JANX revenue by date.
8.083M
-6.12%		10.588M
30.99%		10M
-5.55%		8.561M
-14.39%		6.939M
-18.95%		31.847M
358.96%		77.996M
144.91%		259.02M
232.09%		655.49M
153.07%		1.113B
69.80%		1.516B
36.21%
EBITDA
YoY % growth
JANX ebitda by date.JANX ebitda by date.
-71.024M
-7.21%		-96.787M
-36.27%		-155.638M
-60.80%		-214.751M
-37.98%		-262.25M
-22.12%		-282.719M
-7.81%		-2.496B
-782.70%		-191.607M
92.32%		-56.273M
70.63%		86.333M
253.42%		256.87M
197.53%
EBIT
YoY % growth
JANX ebit by date.JANX ebit by date.
-72.979M
-8.78%		-98.847M
-35.45%		-157.667M
-59.51%		-211.176M
-33.94%		-273.103M
-29.32%		-325.221M
-19.08%		-341.352M
-4.96%		-278.19M
18.50%		29.29M
110.53%		341.65M
1,066.44%		854.12M
150.00%
Operating Margin
JANX operating margin by date.JANX operating margin by date.
-902.87%-933.58%-1,576.67%-2,466.72%-3,935.77%-1,021.20%-437.65%-107.40%4.47%30.70%56.34%
EPS
YoY % growth
JANX eps by date.JANX eps by date.
-1.34
11.84%		-1.28
4.48%		-1.83
-42.97%		-2.75
-50.24%		-3.33
-21.15%		-4.00
-20.04%		-4.14
-3.51%		-2.28
44.97%		0.60
126.35%		4.02
569.17%		8.13
102.40%

All data in USD

Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates

Q1 / 26 Q2 / 26 Q3 / 26 Q4 / 26 Q1 / 27 Q2 / 27 Q3 / 27 Q4 / 27 Q1 / 28 Q2 / 28 Q3 / 28 Q4 / 28
EPS
Q2Q % growth		-0.57
-49.00%		-0.63
-13.78%		-0.70
-80.60%		-0.69
-35.49%		-0.67
-18.51%		-0.70
-12.53%		-0.74
-5.34%		-0.78
-12.83%		-0.83
-23.90%		-0.78
-10.81%		-0.71
4.45%		-0.71
8.42%
Revenue
Q2Q % growth		2.635M788.185K92.728K
-99.07%		6.035M
-100.00%
-100.00%
-100.00%
-100.00%
EBITDA
Q2Q % growth		-42.524M
-23.69%		-33.976M
22.88%		-52.77M
-56.63%		-55.243M
-36.84%		-55.08M
-29.53%		-56.1M
-65.12%		-57.12M
-8.24%		-58.14M
-5.24%		N/AN/AN/AN/A
EBIT
Q2Q % growth		-42.277M
-21.15%		-45.035M
0.18%		-52.41M
-48.68%		-45.65M
-7.66%		-53.3M
-26.07%		-55.08M
-22.31%		-56.87M
-8.51%		-58.67M
-28.52%		-56.386M
-5.79%		-57.508M
-4.41%		-58.66M
-3.15%		-59.833M
-1.98%

All data in USD

Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data

JANX Yearly Revenue VS EstimatesJANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B
JANX Yearly EPS VS EstimatesJANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 -4 6 8

Long Term Forward Growth Forecast Summary

Long Term EPS Growth (CAGR)

EPS Next 3 Year
-29.76%
EPS Next 5 Year
-4.47%

Long Term Revenue Growth (CAGR)

Revenue Next 3 Year
45.87%
Revenue Next 5 Year
90.74%

Long Term EBIT Growth (CAGR)

EBIT Next 3 Year
-19.03%
EBIT Next 5 Year
-2.71%
→ Find peers expecting at least 20% CAGR revenue growth over the next 3 years

JANUX THERAPEUTICS INC / JANX Forecast FAQ

Can you provide the average price target for JANUX THERAPEUTICS INC stock?

26 analysts have analysed JANX and the average price target is 54.57 USD. This implies a price increase of 275.57% is expected in the next year compared to the current price of 14.53.

Can you provide the upcoming earnings date for JANUX THERAPEUTICS INC?

JANUX THERAPEUTICS INC (JANX) will report earnings on 2026-05-06, after the market close.

What are the consensus estimates for JANX stock next earnings?

The consensus EPS estimate for the next earnings of JANUX THERAPEUTICS INC (JANX) is -0.57 USD and the consensus revenue estimate is 2.63M USD.

Can you provide the consensus rating for JANUX THERAPEUTICS INC stock?

The consensus rating for JANUX THERAPEUTICS INC (JANX) is 84.6154 / 100 . This indicates that analysts generally have a positive outlook on the stock.